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Abstract
Background: Oncolytic herpes simplex virus (HSV) can replicate in and kill cancer cells while sparing the adjacent
normal tissue. Hepatocellular carcinoma (HCC) is amongst the most common and lethal cancers, especially in Third
World countries. In this study, the cytotoxicity of a third-generation oncolytic HSV, G47Δ, was investigated in different
human HCC cell lines and in an immortalized human hepatic cell line. Additionally, subcutaneous models of HCC were
established to evaluate the in vivo anti-tumor efficacy of G47Δ.
Methods: The HepG2, HepB, SMMC-7721, BEL-7404, and BEL-7405 human HCC cell lines and the HL-7702 human
hepatic immortalized cell lines were infected with G47Δ at different multiplicities of infection (MOIs). The viability of
infected cells was determined, and the G47Δ replication was identified by X-gal staining for LacZ expression. Two
subcutaneous (s.c.) HCC tumor models of HCC were also established in Balb/c nude mice, which were intratumorally
(i.t.) treated with either G47Δ or mock virus. Tumor volume and mouse survival times were documented.
Results: More than 95% of the HepG2, Hep3B,and SMMC-7721 HCC cells were killed on by day 5 after infection with a
MOI’s of 0.01. For the HL-7702 human hepatic immortalized cells, 100% of the cells were killed on by day 5 after infection
with a MOI’s of 0.01. The BEL-7404 HCC cell line was less susceptible with about 70% cells were killed by day 5 after
infection with a MOI’s of 0.01. Whereas the BEL-7405 HCC cells were the least susceptible, with only 30% of the
cells were killed. Both the SMMC-7721 and BEL-7404 cells form aggressive sc tumor models. G47Δ replicates in
the tumors, such that most of the tumors regressed after the G47Δ-treatment, and treated tumor-bearing mice
survived much longer than the control animals.
Conclusions: G47Δ effectively kills human HCC cells and an immortalized hepatic cell line at low MOI. Intra-tumor
injection of G47Δ can induce a therapeutic effect and prolong the survival of treated mice bearing SMMC-7721 and
BEL-7404 subcutaneously (s.c.) tumors. Thus, G47Δ may be useful as a novel therapeutic agent for HCC.
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Introduction
Hepatocellular carcinoma (HCC) is one of the most
common and lethal malignancies worldwide [1-3]. It is
more frequent among men than women, and the mor-
bidity increases gradually with age. More than one mil-
lion worldwide cases of HCC occur each year [4]. The
incidence is highest in Third World countries, and a ris-
ing incidence has been recently been observed in devel-
oped countries.
The major etiological factors associated with HCC are
infection with the hepatitis B (HBV) or C (HCV) viruses,
chronic inflammatory liver lesions, necrosis of hepato-
cytes and subsequent fibrosis, long term exposure to
high levels of AFBI or vinyl chloride in the diet, and
heavy alcohol consumption [5]. At least one of these
etiological factors can be identified, either alone or in
combination with another factor [6-8]. Both HBV and
HCV cause acute and chronic infections that are associ-
ated with over 80% of HCC cases worldwide, with most
infected individuals remaining asymptomatic for many
years [9,10]. It is estimated that approximately 10% to
40% of chronic HBV carriers eventually suffer from liver
cancer [9,11].
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to have curative potential: hepatic resection, liver trans-
plantation, percutaneous radiofrequency ablation, and
transarterial chemoembolization [12,13]. Recent progress
in these treatment approaches has contributed to the
improved survival rate of HCC patients [13]. Improve-
ments in surgical techniques have led to significant ad-
vances in liver surgery, which have led to a substantial
reduction in HCC mortality. The parallel development
of laparoscopic surgery has also provided several advan-
tages [14], although it is not routinely used [15].
However, there are limitations on these therapeutic op-
tions. HCC treatment depends on the stage of the tumor,
the clinical characteristics, and the degree of liver dysfunc-
tion [16]. Patients must be diagnosed at an early stage and
fulfill certain criteria. Unfortunately, HCC patients remain
asymptomatic, and the majority of patients are not diag-
nosed until the tumor is in an advanced, non-resectable
stage. Systemic chemotherapy is also disappointing, with
low response rates and high toxicity. Treatment possibil-
ities for these patients are limited. Hence, a new strategy
that targets HCC specifically and effectively is needed.
One of the major goals of antitumor therapies is to
target tumor cells selectively and specifically, while spar-
ing adjacent healthy tissue from destruction. Oncolytic
herpes viruses have been proposed as useful anti-tumor
agents that kill dividing tumor cells but not normal tis-
sue [17]. These viruses may be a new treatment strategy
for malignant hepatic tumors.
Oncolytic herpes simplex viruses (HSVs) provide a po-
tential therapeutic strategy that targets malignant tumors
without damaging adjacent normal tissue. Replication of a
single HSV can kill the host cell and release new virions,
which can infect adjacent cells. Because these viruses des-
troy tumor cells by oncolysis, they have no cross-resistance
with other therapy strategies, such as radiotherapy and
chemotherapy; thus, they can serve as a complement to
these therapeutic approaches.
Since oncolytic HSV was first described to treat
brain tumors in 1991 [18], the unique biological char-
acteristics of HSV have been improved by the develop-
ment of additional HSV vectors that confer safety and
specificity [19]. Over 20 different oncolytic HSV vec-
tors have been evaluated in a large variety of different
tumor types [19], including human pancreatic, gastric,
and prostate cancer and mouse bladder and colorectal
cancer [20-26]. Currently, six oncolytic HSV vectors,
G207, G47Δ, 1716, HF10, NV1020, and Oncovex
GM-CSF
(talimogene laherparepvec) have progressed to clinical tri-
als, with Oncovex
GM-CSF successfully reaching its primary
endpoint in a randomized phase III trial for metastatic
melanoma [19,27-29].
The virus investigated in this study is a third gener-
ation oncolytic HSV, G47Δ. It contains three principle
mutations that result in its selective cytotoxicity to tumor
cells. The γ34.5 gene precludes the shut-off of protein syn-
thesis in host cells [19], and the γ34.5-deletion limits virus
replication to cells lacking innate immune responses. The
UL39 gene encodes for ICP6, the large subunit of viral ri-
bonucleotide reductase, which is a key enzyme for deoxy-
ribonucleic acid synthesis in nondividing cells [19]. A lacZ
gene insertion in the UL39 gene inactivates it and blocks
virus DNA replication in normal cells [21]. Deletion of the
ICP47 gene places the US11 gene under the control of the
immediate-early α47 promoter, which results in the ampli-
fication of γ34.5- mutant growth. Furthermore, the
ICP47- mutation increases MHC class I presentation,
which stimulates lymphocytes and decreases Natural
Killer (NK) cytolysis of host cells [30]. These important
features enhance the antitumor immune responses fol-
lowing treatment with G47Δ.
In this study, we investigated the cytotoxic effects of
G47Δ on five human HCC cell lines and one immortal-
ized human hepatic cell line. Furthermore, we evaluated
the therapeutic effects of G47Δ in s.c. xenograft models
of two human HCC cell lines.
Materials and methods
Ethics statement
The animal experiments in this study were conducted
under the institutional guidelines of the Guangdong
Province and approved by the Use Committee for Animal
Care and the Sun Yat-sen University Institute Research
Ethics Committee.
Cells and virus
The HepG2 and Hep3B HCC cell lines (obtained from
Dr. Qi Zhang, Laboratory of Hepatic Disease of the
Third Affiliated Hospital of Sun Yat-sen University,
Guangzhou, China) and Vero cells (African green mon-
key kidney, purchased from The Committee on Type
Culture Collection of Chinese Academy of Sciences,
Shanghai, China) were cultured at 37°C and 5% CO2 in
DMEM with glucose (4.5 g/l, Mediatech, Inc., Herndon,
VA) that was supplemented with 10% fetal calf serum
(Hyclone Laboratories, Logan, UT). The SMMC-7721,
BEL-7404, and BEL-7405 HCC and the HL-7702 human
hepatic immortalized cell lines (obtained from Dr. Qi
Zhang, Laboratory of hepatic disease of the Third Affili-
ated Hospital of Sun Yat-sen University, Guangzhou,
China) were cultured at 37°C and 5% CO2 in RPMI1640
with glucose (4.5 g/l, Mediatech, Inc., Herndon, VA) that
was supplemented with 10% fetal calf serum (Hyclone
Laboratories, Logan, UT).
The G47Δ oncolytic herpes simplex virus was pro-
vided by MediGene, Inc. (San Diego, CA), and propa-
gated in Vero cells cultured in DMEM containing 3%
IFCS (inactivated fetal calf serum) at 34.5°C, as has been
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luted in PBS/1% IFCS. Vero cells were infected with a
MOI of 0.02-0.03 and incubated in a 37°C (5% CO2) in-
cubator. After 90 minutes, the viral inoculum was re-
moved, DMEM/3% IFCS was added, and cells were
incubated at 34.5°C (5% CO2) for approximately 2–3
days until total CPE occurred (the cells were rounded
and refractive). Finally, the infected cells were harvested
and resuspended in a 1:1 mix of DMEM (no serum) and the
virus buffer [150 mM NaCl/20 mM Tris (pH 7.5)]. The cell
suspension was rapidly frozen on EtOH/dry ice, and viral re-
lease was achieved by repeating the freeze-thaw process 3
times to lyse the cells. The cell debris was removed by low-
speed centrifugation (2000 g for 10 min at 4°C). A plaque
assay on the resultant G47Δ progeny was performed on
Vero cells at 37°C to determine the viral titer.
In vitro cytotoxicity
For cytotoxicity assay, cells were seeded in 6-well plates
at 1 ×10
5 cells per well. The cells were infected with
G47Δ at a MOI of 0.01 and 0.1 when the cells were 50%
confluent, while the controls were mock infected with
PBS. After 24-hour incubation at 37°C, the number of sur-
viving cells was counted everyday with a hemocytometer;
the cells were washed twice with 1 ml of phosphate-
buffered saline (PBS) to eliminate floating cells prior to
counting. X-gal staining was performed daily, as described
below, to show the infected cells.
X-gal histochemistry
On days 1–5 post-infection, the culture medium was re-
moved, and the cells were fixed with 0.2% glutaraldehyde/2%
paraformaldehyde for 5 min. The cells were then washed 3
times with PBS and incubated with X-gal substrate solution
[PBS (pH 7.2), containing 0.5 mg/ml 5-bromo-4-chloro-3-
indolyl-β-D-galactopyranoside,5 mmol/L potassium ferri-
cyanide, 5 mmol/L potassium ferrocyanide, 2 mmol/L
magnesium chloride] at 37°C for 2 hours.
Animal studies
Four-week-old male Balb/c nude mice were purchased
from the Shanghai Institutes for Biological Sciences,
Figure 1 The cytotoxicity of three HCC cell lines in vitro.A , X-gal staining of HepG2 cells infected with G47Δ. Monolayers of HepG2 cells in
6-well dishes were infected with G47Δ or control vehicle and incubated with DMEM/1% heat-inactivated FBS at 37°C. On each of the 5 days
following infection, the cells were stained with X-gal solution. The infected cells express Lac Z and stained blue. B, X-gal staining of Hep3B
cells infected with G47Δ. C, X-gal staining of BEL-7405 cells infected with G47Δ. D, E and F, Monolayers of the HepG2, Hep3B and BEL-7405
cells in 6-well dishes were infected with G47Δ with MOI = 0.01 or MOI=0.1, incubated in DMEM/1% heat-inactivated FBS at 37°C, and counted
using a Coulter Counter on the days indicated. The average numbers of cells from duplicate wells are plotted as percentages of the mock wells.
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cage. Each mouse was anesthetized with an i.p. injec-
tion of 0.60 to 0.80 ml 10% Chloral Hydrate. All the
animal procedures were approved by the Sun Yat-sen
University Institute Research Ethics Committee and
t h eU s eC o m m i t t e ef o rA n i m a lC a r e .T h em i c ew e r e
monitored daily for palpable (approximate 5-mm max-
imal diameter) tumor formation, and the tumors were
measured using a Vernier caliper (the length was desig-
nated as “a”, and the width was designated as “b”). The
animals were weighed twice weekly.
Subcutaneous tumor treatment
The HCC SMMC-7721 (2×10
6) and BEL-7404 (3×10
6)
cells were suspended in 100 μlo fR P M I1 6 4 0c o m p l e t e
culture with 25% Matrigel (BD Biosciences) and implanted
subcutaneously (s.c.) into the left flanks of 4-week-old
nude mice. When the s.c. tumors were palpable, the s.c.
tumors were inoculated twice weekly for two weeks with
2×10
7/50 ul of G47Δ or with the virus buffer [150 mM
NaCl, 20 mM Tris, (pH 7.5)] as a control. The tumor size
was measured by Vernier calipers, and the tumor volume
was calculated (V = a × b
2/2). If the animals appeared
moribund (lethargy, a hunched or recumbent posture, a
rough coat or limited ambulatory movements in response
to stimulation) or the maximal diameter of their tumors
exceeded 18 mm, they were sacrificed and the date of death
was recorded for the survival studies. The s.c. tumors were
excised and then fixed in formaldehyde and embedded in
paraffin for histological staining (hematoxylin-eosin).
Virus biodistribution studies
The SMMC-7721 and BEL-7404 s.c. carcinoma-bearing
Balb/c mice were treated 4 times with 2× 10
7 pfu/50 ul
of G47Δ, as described above. The s.c. tumors were re-
moved and embedded with tissue freezing medium
Figure 2 The cytotoxicity of two HCC cell lines and one human hepatic immortalized cell line. A, X-gal staining of BEL-7404 cells infected
with G47Δ. Monolayers of BEL-7404 cells in 6-well dishes were infected with G47Δ or control vehicle and incubated with DMEM/1% heat-inactivated
FBS at 37°C. On each of the 5 days following infection, the cells were stained with X-gal solution. The infected cells express Lac Z and stained
blue. B, X-gal staining of SMMC-7721 cells infected with G47Δ. C, X-gal staining of HL-7702 cells infected with G47Δ. D, E and F, Monolayers
of BEL-7404, SMMC-7721 and HL-7702 cells in 6-well dishes were infected with G47Δ with MOI=0.01 or MOI=0.1, incubated in DMEM/1%
heat-inactivated FBS at 37°C, and counted using a Coulter Counter on the days indicated. The average numbers of cells from duplicate wells
are plotted as percentages of the mock wells.
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(10 μm-thick) were prepared for biochemical staining
of the LacZ enzyme. The sections were fixed with 2%
paraformaldehyde in PBS for 10 minutes and washed
with PBS 3 times for 15 min. Next, slides were incu-
bated with PBS containing 2 mmol/L magnesium chloride,
0.01% sodium deoxycholate, and 0.02% NP40 for 10 minutes
at 4°C. The sections were stained with a substrate solution
[PBS (pH 7.2), containing 1 mg/mL 5-bromo-4-chloro-3-
indolyl-h-D-galactopyranoside, 5 mmol/L potassium
ferricyanide, 5 mmol/L potassium ferrocyanide, 2 mmol/L
magnesium chloride, 0.01% sodium deoxycholate, and
0.02% NP40] at 34°C for 4 hours or over-night. The
sections were washed with PBS/2 mmol/L EDTA and
counterstained with eosin before mounting.
Results
In vitro cytotoxicity
To assess the susceptibility of human HCC cells and a
hepatic immortalized cell line to oncolytic HSV G47Δ
cytotoxicity, monolayers of the HepG2, Hep3B, SMMC-
7721, BEL-7404, and BEL-7405 human HCC cells and
the HL-7702 human hepatic immortalized cell line
were infected with G47Δ at low MOI’s( M O I = 0 . 0 1 ,
MOI = 0.1). By day 5, more than 95% and 100% of the
HepG2, Hep3B and SMMC-7721 HCC cells had been
killed after infection with MOI’s of 0.01 and 0.1, re-
spectively (Figure 1D, E and Figure 2E), similar to the
HL-7702 human hepatic immortalized cells (Figure 2F).
A slight decrease in effect was observed in the BEL-7404
hepatocarcinoma cells; more than 70% and 90% of the
cells had been killed by day 5 after infection with MOI’so f
0.01 and 0.1, respectively (Figure 2D), while the BEL-7405
hepatocarcinoma cells were less sensitive, 29.9% and
57.7% of the cells killed by day 5 after infection with
MOI’s of 0.01 and 0.1, respectively (Figure 1F). The in-
fected cells were stained by X-gal histochemistry (G47Δ
contain the lacZ transgene in the ICP6 region). The in-
fected cells and the spread of the G47Δ viruses are shown
by the blue staining in Figure 1A, B and Figure 2A, B.
Efficacy of G47Δ on s.c. hepatocarcinoma tumors
The SMMC-7721 and BEL-7404 cells were used for s.c. im-
plantation in vivo.. S.c. tumors were established in the left
f l a n ko fm a l eB a l b / cn u d em i c e ,f o l l o w e db yi n t r a t u m o r a l
injection with G47Δ when the tumors were palpable. To
evaluate virus replication in vivo, the G47Δ-treated mice
were sacrificed, and X-gal histochemistry was performed
on the sectioned s.c. tumors. The blue-stained areas repre-
sent G47Δ replication (Figure 3B, D).
Similar to the in vitro results, inoculation with G47Δ
(2 × 10
7 pfu, four times) elicited a prominent antitumor
effect and significantly inhibited tumor growth. Follow-
ing G47Δ treatment, complete regression was observed
in 5 of 6 mice bearing s.c. SMMC-7721 tumors and in 4
of 6 mice bearing BEL-7404 tumors (Figure 4C, G). The
animals were sacrificed on day 82 (for SMMC-7721)
or day 75 (for BEL-7404), by which time the tumors
Figure 3 Established s.c. tumors from HCC SMMC-7721 and BEL-7404 cells. The cells were suspended in 100 μl of RPMI 1640 complete
culture with 25% Matrigel (BD Biosciences) and subcutaneously implanted into the left flanks of 4-week-old nude mice. When the s.c. tumors
were palpable, mice were inoculated into the s.c. tumor twice a week with 2× 10
7/50 ul of G47Δ or virus buffer [150 mM NaCl, 20 mM Tris,
(pH 7.5)] for control. H-E staining of SMMC-7721 (A) and BEL-7404 (C) s.c. tumors (×200). Coronal sections through SMMC-7721 (B) and BEL-7404
(D) s.c. tumors 3 days after G47Δ (2×10
7 pfu) injection to illustrate the virus replication in the s.c. tumors. Sections were stained with X-gal, and
counterstained with eosin to identify cells containing replicating G47Δ (blue).
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volume was calculated (V=a× b
2/2). The animals were sacrificed if they seemed moribund or the maximal diameter of their tumors exceeded
18 mm, and that day was recorded as the date of death for the survival analysis. G47Δ significantly delayed tumor progression compared with
mock treatment. The tumors of 5 SMMC-7721 and 4 BEL-7404 mice in the treated groups regressed completely. A, The mean tumor volumes in
the virus-treated and mock-treated SMMC-7721 groups at different times. B and C, The growth of individual tumors in the mock and virus treated
SMMC-7721 groups. D, The median survival time for the mice with s.c. SMMC-7721 tumors was increased from 27.5 days for the mock-treated
animals to over 82 days for the G47Δ-treated animals. E, The mean tumor volumes in the virus-treated and mock-treated BEL-7404 groups
at different times. F and G. The growth of individual tumors in the mock and virus treated BEL-7404 groups. H, The median survival time for
the mice with s.c. BEL-7404 tumors was increased from 21 days for the mock-treated animals to over 75 days for the G47Δ-treated animals.
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18 mm in maximal diameter. The G47Δ treatment
significantly extended the survival of the mice bearing
the s.c. SMMC-7721 and BEL-7404 tumors, with me-
dian survival times of 82 and 75 days, respectively,
compared to median survival times of 27.5 and 21 days,
respectively, in the mock treated groups (P< 0.05,
log-rank test) (Figure 4D, H).
Discussion
We evaluated the cytopathic effects of third-generation
oncolytic HSV G47Δ on human HCC and immortalized
hepatic cells. Additionally, we demonstrated the therapeutic
value of HSV G47Δ in the treatment of HCC in vivo.
G47Δ has three deletions/mutations, γ34.5, UL39 and
α47, that restrict replication to tumor cells. γ34.5 is re-
quired for HSV to replicate in the brain or cause enceph-
alitis [31-33]. The protein product of γ34.5 precludes the
halting of host protein synthesis in infected cells by de-
phosphorylating eIF2α [34]. γ34.5
− mutants lose neuro-
virulence, and their replication is attenuated in normal
cells. However, the replication of γ34.5
− mutants is un-
affected in dividing tumor cells. The virus is further mu-
tated by a lacZ gene insertion into the gene encoding
ICP6, which is required for efficient viral growth in non-
dividing cells but not in many dividing cells in tissue
cultures [35]. ICP6 is the large subunit of the viral ri-
bonucleotide reductase, which is a key enzyme required
synthesizing deoxyribonucleic acid in nondividing cells
[35,36]. Without this enzyme, DNA replication is blocked
in normal cells. Mammalian ribonucleotide reductase is
elevated in tumor cells relative to normal cells; thus, the
insertional inactivation of the gene encoding ICP6 guaran-
tees the preferential replication of G47Δ in tumor cells
[36]. Additionally, the mutation in the ICP6 gene makes
the virus more sensitive to acyclovir and ganciclovir [37],
which can augment its safety for clinical use. In addition
to its direct cytotoxic effects, G47Δ is also capable of in-
ducing antitumor immune responses [38-40]. The α47
gene binds to the transporter associated with antigen pres-
entation (TAP) and blocks peptide loading of MHC class I
molecules [41]. There is a α47 deletion in G47Δ [31]. This
deletion increases MHC class I presentation, stimulates
lymphocytes, and decreases NK cytolysis of infected cells,
which can broaden the activation of an antitumor immune
response [30]. This ability is an important feature for treat-
ing metastatic tumors, particularly in patients with severely
limited treatment options. The α47 mutation also places
the late US11 gene under the control of the immediate-
early α47 promoter. This shift in control blocks the halting
of host protein synthesis and results in amplified growth of
γ34.5
− mutants and a boost in the cytotoxicity in tumor
cells [34]. These multiple mutations make pathogenic
reversion due to recombination nearly impossible and
guarantee an important inherent safety mechanism for
G47Δ treatment. The combination of safety and effi-
cacy led us to explore G47Δ as a therapeutic agent for
malignant tumors. Recently, G47Δ has entered phase 1
clinical trial for progressive glioblastoma.
Our results demonstrate that G47Δ can effectively kill
different human HCC cell lines. Cytotoxic effects were
observed in the HepG2, Hep3B, SMMC-7721, BEL-7404
and BEL-7405 cell lines. The efficiency of G47Δ in kill-
ing malignant HCC cells and inhibiting the growth of
xenograft tumors, offers a promising therapeutic strategy
in treating human hepatic tumors. As typical surgical re-
section may be not always possible or would induce serious
complications, this new therapeutic treatment strategy for
hepatic cancer should be of benefit to patients with hepatic
cancer, especially those with late-stage cancer that have lost
the opportunity of surgery. We also demonstrated the cy-
topathic effects of G47Δ on the HL-7702 human hepatic
immortalized cell line at a very low MOI. Interestingly,
immortalization of Schwann cells enhances their permis-
siveness to oncolytic HSV G207 [42]. Bypass of senescence
and immortalization are considered to be early steps in
tumor development, and thus G47Δ m a yb ea c t i v ea ta n
early stage of tumorigenesis. So far, G47Δ has not posed a
safety concern; thus, it could be used not only as a
therapeutic strategy but also a preventive agent in pre-
malignant diseases, such as hepatitis and cirrhosis.
To investigate the in vivo HCC antitumor effects of
G47Δ, we established s.c. xenograft models of HCC
using 2 different cell lines: SMMC-7721 and BEL-7404.
G47Δ was administered to the Balb/c nude mice twice a
week for 2 weeks without any observable toxicity. A
higher survival rate and significant reduction in tumor
growth relative to the mock-treated groups were ob-
served after G47Δ therapy. Many of s.c. tumors from
both the SMMC-7721 and BEL-7404 groups of G47Δ-
treated Balb/c nude mice gradually regressed, suggesting
that G47Δ has the potential to effectively inhibit differ-
ent types of HCC tumors in clinical applications.
In conclusion, the third-generation oncolytic HSV G47Δ
was effective as a tumoricidal agent in both HCC and im-
mortalized hepatic cells. This feature suggests its use as
both a therapeutic and preventive agent for human HCC.
Intratumoral injection of G47Δ induced an obvious thera-
peutic effect on HCC, which may lead to future clinical ap-
plications in cancer therapy.
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